- The HARMONY Big Data Platform is collecting 45,000 anonymized patient records, becoming one of the largest of its kind in the world;
- The goal of HARMONY is to help drive the development of better therapies and improve care for patients with various hematologic malignancies;
- The HARMONY Alliance is a public-private partnership of more than 80 Partners and Associated Members funded by the Innovative Medicines Initiative for a period of 5 years (2017-2021).
The European public-private partnership ‘HARMONY” announced today at the 24th Annual Congress of the European Hematology Association, that its innovative Big Data Platform has reached an important milestone capturing anonymized data records from 45,000 patients with blood cancers.
The HARMONY Big Data Platform is one of the largest of its kind in the world and the team is aiming to expand it to at least 100,000 patients during the lifetime of the HARMONY Alliance.
“To answer the key outstanding questions in the field of hematology, we need harmonized and high-quality data on treatment outcomes in thousands of patients which today are contained in multiple clinical trials and registries”, says Mario Boccadoro, University of Turin, Leadership of the HARMONY Research Project on Multiple Myeloma. “HARMONY has developed technical and organizational procedures to overcome these obstacles, allowing the alliance to assemble anonymized data records from thousands of European patients into one harmonized Big Data Platform.”
HARMONY researchers are already mining the Big Data Platform to address pressing research questions such as: Does one specific treatment provide improved outcomes in patients with aggressive Multiple Myeloma?; Which subgroups of Myelodysplastic Syndromes patients benefit from treatment with hypomethylating agents? What are the most important outcomes for Acute Myeloid Leukemia, according to patients, clinicians, health authorities, and the pharmaceutical industry?
“Mining this unique Big Data Platform to address pressing research questions will give us better insight in the molecular landscape of blood cancers and the prognostic value of disease related variables, hence increasing our understanding of their pathophysiology. Making use of Big Data analytics in blood cancer research will lead us faster to identifying novel drug targets”, says Bruno Costa, Celgene and representing the EFPIA members in HARMONY. “Ultimately, our goal is that, together, we can accelerate drug development, regulatory evaluation, access appraisal, and treatment strategies to improve the care of patients with these blood cancers.”
More info: Harmony News